Learn­ing from past mis­takes, Cen­trex­ion clears a big PhI­Ib hur­dle for its pain drug

Jef­frey Kindler’s biotech start­up Cen­trex­ion is boast­ing about its lead drug’s suc­cess in a Phase IIb pain study for knee os­teoarthri­tis.

The ex-Pfiz­er CEO’s Boston …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER